Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Receivables - Other (2017 - 2025)

Historic Receivables - Other for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $936000.0.

  • Autolus Therapeutics' Receivables - Other rose 5652.17% to $936000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $936000.0, marking a year-over-year increase of 5652.17%. This contributed to the annual value of $1.4 million for FY2024, which is 17538.76% up from last year.
  • Autolus Therapeutics' Receivables - Other amounted to $936000.0 in Q3 2025, which was up 5652.17% from $665000.0 recorded in Q2 2025.
  • Autolus Therapeutics' Receivables - Other's 5-year high stood at $2.4 million during Q3 2023, with a 5-year trough of $384000.0 in Q4 2021.
  • For the 5-year period, Autolus Therapeutics' Receivables - Other averaged around $948000.0, with its median value being $736000.0 (2024).
  • In the last 5 years, Autolus Therapeutics' Receivables - Other soared by 27369.79% in 2022 and then tumbled by 7462.88% in 2024.
  • Quarter analysis of 5 years shows Autolus Therapeutics' Receivables - Other stood at $384000.0 in 2021, then soared by 273.7% to $1.4 million in 2022, then crashed by 64.04% to $516000.0 in 2023, then surged by 175.39% to $1.4 million in 2024, then tumbled by 34.13% to $936000.0 in 2025.
  • Its Receivables - Other was $936000.0 in Q3 2025, compared to $665000.0 in Q2 2025 and $423000.0 in Q1 2025.